A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
B-cell Lymphoma · Non-Hodgkin Lymphoma · B-cell Malignancy · Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · Follicular Lymphoma · Mantle Cell Lymphoma · Marginal Zone Lymphoma · Large B-cell Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +7.7
3 insiders sold shares within a month
Since Oct 14, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 120 (planned)
- Started
- Mar 10, 2023
- Main results expected
- Jan 2030
- Fully finished
- Feb 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities
Measured over: From CTX112 infusion up to 28 days post-infusion
Phase 2 (Cohort Expansion): Objective response rate
Measured over: From CTX112 infusion up to 60 months post-infusion
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 7.7, since 2026-10-14, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05643742 · record last updated 2025-11-14 · checked 2026-11-09 15:47 UTC